As Sanofi attempts to bounce back from a tough year of clinical readouts, the French pharma has touted longer-term ph...
Sanofi highlights longer-term phase 2 extension data for its Teva-partnered inflammatory bowel disease candidate, framing the result as a key pipeline opportunity amid a tough year of clinical setbacks.
Why it mattersPhase 2 extension data for the Teva-partnered IBD candidate justifies reprioritizing R&D resources toward GI programs.